A detailed history of Quadrant Capital Group LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 5,059 shares of IOVA stock, worth $39,662. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,059
Previous 5,059 -0.0%
Holding current value
$39,662
Previous $40,000 17.5%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

BUY
$3.3 - $8.89 $15,437 - $41,587
4,678 Added 1227.82%
5,059 $41,000
Q3 2023

Nov 14, 2023

SELL
$4.44 - $8.79 $6,362 - $12,596
-1,433 Reduced 79.0%
381 $1,000
Q2 2023

Aug 09, 2023

BUY
$5.36 - $9.06 $696 - $1,177
130 Added 7.72%
1,814 $12,000
Q4 2022

Feb 10, 2023

BUY
$5.62 - $10.0 $8,722 - $15,520
1,552 Added 1175.76%
1,684 $10,000
Q3 2022

Nov 10, 2022

SELL
$9.53 - $13.11 $1,210 - $1,664
-127 Reduced 49.03%
132 $1,000
Q2 2022

Aug 09, 2022

SELL
$6.38 - $18.33 $140 - $403
-22 Reduced 7.83%
259 $3,000
Q1 2022

May 06, 2022

SELL
$12.38 - $19.1 $9,111 - $14,057
-736 Reduced 72.37%
281 $4,000
Q4 2021

Feb 01, 2022

BUY
$16.55 - $27.63 $4,038 - $6,741
244 Added 31.57%
1,017 $19,000
Q3 2021

Nov 12, 2021

BUY
$20.35 - $26.63 $11,090 - $14,513
545 Added 239.04%
773 $19,000
Q2 2021

Aug 09, 2021

BUY
$16.33 - $33.07 $2,629 - $5,324
161 Added 240.3%
228 $6,000
Q1 2021

May 12, 2021

BUY
$28.67 - $52.59 $57 - $105
2 Added 3.08%
67 $2,000
Q4 2020

Feb 16, 2021

BUY
$28.04 - $50.26 $869 - $1,558
31 Added 91.18%
65 $3,000
Q3 2020

Nov 13, 2020

BUY
$27.75 - $36.3 $943 - $1,234
34 New
34 $1,000
Q2 2020

Aug 13, 2020

SELL
$27.21 - $41.0 $4,081 - $6,150
-150 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$19.54 - $38.85 $2,931 - $5,827
150 New
150 $4,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.24B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.